Compare Boston Scientific Corporation (BSX) vs Futu Holdings Ltd (FUTU) Price & Performance

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.

Futu Holdings Limited (FUTU) trades at $105.31, down 3.12% on the day. The stock shows strong fundamentals with a P/E of 11.63 and robust profitability, including a net income margin of 41.83% and ROE of 28.09%. Revenue grew to $22.85B in 2025, and cash flow from operations surged to $31.0B in 2024. Technical indicators are bullish, with moving averages supporting an uptrend and key support at $103. However, recent earnings misses and a securities class action lawsuit pose significant headwinds.

The outlook for FUTU is mixed; strong financial health and analyst consensus leaning buy (58.34%) suggest potential upside, but legal risks and earnings volatility require caution. Investors should weigh solid fundamentals against regulatory and litigation overhangs that could impact near-term performance.